India, Oct. 23 -- Bolt Biotherapeutics, Inc. (BOLT) announced its acquisition of Prana Therapies, Inc. through a stock-for-stock reverse merger to advance Prana's pipeline of half-life-extended multispecific antibodies developed using its proprietary INSPIRE platform.
The acquired pipeline is led by PRA-216, an investigational IL-4Ra/TSLP bispecific antibody currently in Phase 2 development for asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.
A Phase 2 study in eosinophilic esophagitis is also planned, with patient data from all four trials expected beginning in the second quarter of 2027.
Concurrently, Bolt entered into a definitive agreement for a private placement expected to generate $120 million in upfront...